Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

The Prometastatic Ribosomal S6 Kinase 2-cAMP Response Element-binding Protein (RSK2-CREB) Signaling Pathway Up-regulates the Actin-binding Protein Fascin-1 to Promote Tumor Metastasis

Li, D and Jin, L and Alesi, GN and Kim, YM and Fan, J and Seo, JH and Wang, D and Tucker, M and Gu, TL and Lee, BH and Taunton, J and Magliocca, KR and Chen, ZG and Shin, DM and Khuri, FR and Kang, S (2013) The Prometastatic Ribosomal S6 Kinase 2-cAMP Response Element-binding Protein (RSK2-CREB) Signaling Pathway Up-regulates the Actin-binding Protein Fascin-1 to Promote Tumor Metastasis. JOURNAL OF BIOLOGICAL CHEMISTRY. pp. 32528-32538.

Abstract

Metastasis is the leading cause of death in patients with breast, lung, and head and neck cancers. However, the molecular mechanisms underlying metastases in these cancers remain unclear. We found that the p90 ribosomal S6 kinase 2 (RSK2)-cAMP response element-binding protein (CREB) pathway is commonly activated in diverse metastatic human cancer cells, leading to up-regulation of a CREB transcription target Fascin-1. We also observed that the protein expression patterns of RSK2 and Fascin-1 correlate in primary human tumor tissue samples from head and neck squamous cell carcinoma patients. Moreover, knockdown of RSK2 disrupts filopodia formation and bundling in highly invasive cancer cells, leading to attenuated cancer cell invasion in vitro and tumor metastasis in vivo, whereas expression of Fascin-1 significantly rescues these phenotypes. Furthermore, targeting RSK2 with the small molecule RSK inhibitor FMK-MEA effectively attenuated the invasive and metastatic potential of cancer cells in vitro and in vivo, respectively. Taken together, our findings for the first time link RSK2-CREB signaling to filopodia formation and bundling through the up-regulation of Fascin-1, providing a proinvasive and prometastatic advantage to human cancers. Therefore, protein effectors of the RSK2-CREB-Fascin-1 pathway represent promising biomarkers and therapeutic targets in the clinical prognosis and treatment of metastatic human cancers

Item Type: Article
Additional Information: pubid: 226 nvp_institute: NIBR contributor_address: Emory Univ Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA smkang@emory.edu; Cell Signaling Technol Inc, Danvers, MA 01923 USA ; Novartis Inst BioMed Res, Cambridge, MA 02139 USA ; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94107 USA ; Emory Univ Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA ; Emory Univ Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA; Kang, S M; Emory Univ Sch Med, Winship Canc Inst, 1365-C Clifton Rd NE, Atlanta, GA 30322 USA
Date Deposited: 13 Oct 2015 13:12
Last Modified: 13 Oct 2015 13:12
URI: https://oak.novartis.com/id/eprint/22038

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.